242
Registered trials
107
Recruiting
115
Completed trials
105
Sponsors
26
Countries
Phase III:
109
Phase II/III:
15
Phase II:
85
Phase I/II:
10
Phase III/IV:
3
Phase IV:
8
Phase I:
1
Phase I (Other):
2
Phase I (FiH):
9
Oversight events:
4 serious breaches
34 temporary halts
7 urgent safety measures
9 unexpected events
4 corrective measures
across 26 trials
View oversight register →
Indications tested
Non-small cell lung cancer
18
Ovarian cancer
12
Non-small cell lung cancer metastatic
12
Fallopian tube cancer
11
Triple negative breast cancer
9
Non-small cell lung cancer stage III
8
Non-small cell lung cancer stage IV
7
Breast cancer
7
Ovarian epithelial cancer
7
Non-small cell lung cancer stage IIIB
6
Hormone receptor positive HER2 negative breast cancer
5
Endometrial cancer
5
Sponsors using this IMP
Merck Sharp & Dohme LLC
36
AstraZeneca AB
23
Intergroupe Francophone De Cancerologie Thoracique
8
Unicancer
8
Bristol-Myers Squibb Services Unlimited Company
7
Gilead Sciences Inc.
7
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
7
F. Hoffmann-La Roche AG
5
Regeneron Pharmaceuticals Inc.
5
Bristol Myers Squibb International Corporation
4
Daiichi Sankyo Inc.
4
Genmab A/S
4
All trials
242 total-
HARMONi-3 Not authorised
Showing 1–24 of 242 trials